Navigation Links
Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
Date:1/18/2011

," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Such statements include, without limitation, statements regarding: the commercial launch of OFIRMEV; the anticipated U.S. market opportunity for IV acetaminophen; the ability of OFIRMEV to fill unmet medical needs and achieve formulary and market acceptance; and our strategy for building a long-term hospital pain franchise. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Actual future results may differ materially from our current expectations due to the risks and uncertainties inherent in Cadence's business. These risks include our dependence on the successful commercialization of OFIRMEV; the risk that delays in commercially launching or achieving formulary acceptance for OFIRMEV at a substantial number of targeted accounts would enable competitors to further entrench their products and decrease the market potential for OFIRMEV; our ability to ensure an adequate and continued supply of OFIRMEV to successfully launch commercial sales or meet anticipated market demand; OFIRMEV remains subject to substantial, ongoing regulatory requirements; our ability to comply with the terms of our loan agreement; the potential for an event of default under our loan agreement, and the corresponding risk of acceleration of repayment and potential foreclosure on the assets pledged to secure the line of credit; the potential that we may be required to file a lawsuit to defend our patent rights or regulatory exclusivities from challenges by companies seeking to market generic versions of intravenous acetaminophen; our ability to successfully enforce our intellectual property rights and defend our patents; the impact of healthcare reform legislation; the potential that we will require substantial additional funding in order to successfully commer
'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
3. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
4. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
5. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
6. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
7. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... DUBLIN , May 05, 2015 Research ... announced the addition of the "Clinical Laboratory, ... and Forecasts 2015 to 2019 - Europe Version" ... technical developments especially in the area of molecular ... dynamic, growing and evolving world market that is ...
(Date:5/5/2015)... , May 5, 2015   Tocagen ... that David R. Parkinson , M.D., a ... been appointed to the board of directors of ... of experience in oncology clinical development, including leading ... in global approvals of the cancer therapeutics Gleevec®, ...
(Date:5/5/2015)... -- Indianapolis-based medical device manufacturer NICO Corporation is seeing ... including the BrainPath® and Myriad™ technologies offering a ... and then removing affected tissue. More than 1,600 ... institutions throughout the United States ... 12 abstracts, three peer-reviewed publications, and seven presentations ...
(Date:5/4/2015)... YORK , May 4, 2015 ... for granted. But for certain infants with rare, ... death are stark consequences of their impaired immune ... Medical Center have identified an important role for ... resulting from Mycobacterium tuberculosis, the bacterium causing tuberculosis ...
Breaking Biology Technology:European Clinical Laboratory, Molecular Diagnostics and Genomic Testing Services Market 2015-2019 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 2Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 3Tocagen Appoints David R. Parkinson, M.D., to the Board of Directors 4NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 2NICO Corporation Gains Market Expansion after Multiple Published Clinical Articles Support Access Technology for Deep Brain Lesions 3Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3
... China, Feb. 13 /PRNewswire-Asia-FirstCall/ -- China,Biologic Products, Inc. ... one of the leading plasma-based pharmaceutical companies in ... one of its R&D,projects, "High-Purity Human Albumin," will ... , The National Torch ...
... MISSISSAUGA, ON, Feb. 13 /PRNewswire-FirstCall/ - YM BioSciences ... company that identifies, develops and commercializes differentiated products ... results for the second quarter of fiscal 2009, ... we prepared to initiate our two randomized Phase ...
... Acceleration, Channel Effectiveness and Demand Creation Best Practice Findings to ... ... Wilton, CT (PRWEB) February 13, 2009 -- SiriusDecisions, ... practice research and data, today announced that top executives from ...
Cached Biology Technology:China Biologic Products' High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan 2China Biologic Products' High-Purity Human Albumin Research and Development Project to be Listed in the National Torch Plan 3YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 2YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 3YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 4YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 5YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 6YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 7YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 8YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 9YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS 10Senior Executives from HP, IBM and Omniture Headline "Leaders and Lessons Learned" Sales and Marketing Summit 2009 2Senior Executives from HP, IBM and Omniture Headline "Leaders and Lessons Learned" Sales and Marketing Summit 2009 3
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, ... control and security systems is pleased to announce that ... as a consultant and member of its scientific advisory ... widely known as a thought leader in technology-enhanced learning ... Technology Group, and has published studies and books focused ...
(Date:4/20/2015)... -- The announcement comes as demand for ... (GRM), Ireland,s foremost records management company, ... up an impressive track record of clients within the first ... records management sector in Dubai . As ... and employ a further eight staff members at its Irish ...
(Date:4/14/2015)... 14, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces that ... 2015 New York Design Awards under the category  ,Product ... City Design Awards are part of a global multi-disciplinary ... ratings from the marketplace, industry and judging panel. Winners ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... Foundation (IOF) invites you to attend the first ... IOF Regionals: Asia-Pacific Osteoporosis Meeting, to be held ... your calendar: Online registration and abstract submission opens ... An exciting programme has been developed to provide ...
... , Some regions of the deep ocean floor support ... that contains very little oxygen, according to an international ... Oceanography Centre, Southampton. But global warming is likely to ... regions, they warn. The sunlit surface waters ...
... Polytechnic Institute (WPI) research team has received a four-year, ... (NIH) to continue a groundbreaking study of arterial plaque. ... physicians to predict the likelihood of plaque rupture, which ... by Dalin Tang, PhD, professor of mathematical sciences and ...
Cached Biology News:Singapore program to provide clinical insight; showcase for regional research 2Seabed biodiversity in oxygen minimum zones 2Seabed biodiversity in oxygen minimum zones 3WPI receives $1.4 million from NIH for pioneering work on arterial plaque and cardiovascular disease 2WPI receives $1.4 million from NIH for pioneering work on arterial plaque and cardiovascular disease 3
... to CRF The antibody ... CRF sequence that it was ... are found in the paraventricular ... in colchicine treated 4% FA ...
...
Alexa Fluor 647 anti-mouse Qa-2...
Mouse monoclonal [0.T.81] to Lac1 ( Abpromise for all tested applications). Antigen: Recombinant TrpE fusion protein containing full length E. coli Lac1....
Biology Products: